Inhibition of granulocyte migration by tiotropium bromide

Respiratory Research

Volumn 12, Issue 1, 2011, Pages

  Vacca, Gabriela ^a   Randerath, Winfried J ^b   Gillissen, Adrian ^c  

^a Robert Koch Klinik   (Germany)

^b Krankenhaus Bethanien Solingen   (Germany)

^c Department of Thoracic and Cardiovascular Surgery   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CARBACHOL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE B4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MUSCARINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; OXOTREMORINE; PHORBOL 13 ACETATE 12 MYRISTATE; REACTIVE OXYGEN METABOLITE; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; AUTACOID; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC RECEPTOR; SCOPOLAMINE DERIVATIVE;

ARTICLE; BLOOD GAS ANALYSIS; CELL MEDIATED CYTOTOXICITY; CELL MIGRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; FEMALE; FLUORESCENCE ANALYSIS; GENETIC TRANSCRIPTION; GRANULOCYTE; HUMAN; HUMAN CELL; INCUBATION TIME; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION TEST; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL CHEMOTAXIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL CULTURE; CULTURE MEDIUM; DRUG EFFECT; IMMUNOLOGY; MACROPHAGE ACTIVATION; METABOLISM; NEUTROPHIL;

ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; CHOLINERGIC AGONISTS; CHOLINERGIC ANTAGONISTS; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; MALE; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REACTIVE OXYGEN SPECIES; RECEPTORS, MUSCARINIC; SCOPOLAMINE DERIVATIVES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951951764     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-24     Document Type: Article

References (64)

1. Saetta M: Airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160: S17-S20.
2. Saetta M, Finkelstein R, Cosio MG: Morphological and cellular basis for airflow limitation in smokers. Eur Respir J 1994, 7: 1505-1515.
3. Keatings VM, Barnes PJ: Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma andnormal subjects. Am J Respir Crit Care Med 1997, 155: 449-453.
4. O'Donnell RA, Peebles C, Ward JA, Daraker A, Angco G, Broberg P, Pierrou S, Lund L, Holgate ST, Davies DE, et al.: Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 2004, 59: 837-842.
5. Beeh KM, Kornmann O, Buhl R, Culpitt SV, Giembycz MA, Barnes PJ: Neutrophil chemotactic activity of sputum from patients with COPD: Role ofinterleukin 8 and leukotriene B4. Chest 2003, 123: 1240-1247.
6. Traves SL, Culpitt SV, Russell RE, Barnes PJ, Donnelly LE: Increased levels of the chemokines GROα and MCP-1 in sputum samples from patients with COPD. Thorax 2002, 57: 590-510.
7. Mikami M, Llewellyn-Jones CG, Bayley DL, Hill SL, Stockley RA: The chemotactic activity of sputum from patients with bronchiectasis. Am J Physiol 1998, 264: L413-L418.
8. Hogg JC: Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004, 364: 709-721.
9. Chung KF: Cytokines as targets in chronic obstructive pulmonary disease. Curr Drug Targets 2006, 7: 675-681.
10. Beeh KM, Beier J: Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma ? Clin Exp Allergy 2006, 36: 142-157.
11. Gizycki MJ, Hattotuwa KL, Barnes N, Jeffery PK: Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 2002, 57: 799-803.
12. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC: The effect of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002, 165: 1592-1596.
13. Boorsma M, Lutter P, Pol van de MA, Out TA, Jansen HM, Jonkers RE: Long-term effects of budesonide on inflammatory status in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease 2008, 5: 97-104.
14. Bühling F, Lieder N, Kühlmann UC, Waldburg N, Welte T: Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro. Respir Med 2007, 101: 2386-2394.
15. Bos IS, Gosens R, Zuidhof AB, Schaafsma D, Halayko AJ, Meurs H, Zaagsma J: Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparision. Eur Respir J 2007, 30: 653-661.
16. Gosens R, Bos ST, Zaagsma J, Meurs H: Protective effects of tiotropium bromide in the progresse of airway smooth muscle remodeling. Am J Respir Crit Care Med 2005, 171: 1096-1102.
17. Pieper MP, Chaudhary NI, Park JE: Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide. Life Sci 2007, 80: 2270-2273.
18. Racké K, Haag S, Bahulayan A, Warnken M: Pulmonary fibroblasts, an emerging target for anti-obstructive drugs. Naunyn-Schmiedeberg's Arch Pharmacol 2008, 378: 193-201.
19. Gosens R, Nelemans A, Groote Bromhaar MM, McKay S, Zaagsma J, Meurs H: Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Crit Care Med 2003, 28: 257-262.
20. GOLD Executive Committee: Global initiative for chronic obstructive lung disease. www goldcopd com 2007.
21. Haslam PL, Baughman RP: Report of ERS Task Force: guideline for measurement of acellular components and standardization of BAL. Eur Respir J 1999, 14: 245-248.
22. Report of the European Society of pneumology task group on BAL: Technical recommendations and guidelines for bronchalveolar lavage (BAL). Eur Respir J 1989, 2: 561-585.
23. Repetto G, del Peso A, Zurita JL: Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 2008, 3: 1125-1131.
24. Hammond ME, Lapointe GR, Feucht PH, Hilt S, Galleqos CA, Gordon CA, Giedlin MA, Mullenbach G, Tekamp-Olson P: IL-8 induced neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol 1995, 155: 1428-1433.
25. Quan JM, Martin TR, Rosenberg GB, Foster DC, Whitemore T, Goodman RB: Antibodies against the N-terminus of IL-8 receptor A inhibit neutrophil chemotaxis. Biochem Biophys Res Commun 1996, 219: 405-411.
26. Frevert CW, Wong VA, Goodman RB, Goodwin R, Martin TR: Rapid fluorescence-based measurements of neutrophil migration in vitro. J Immunol Meth 1998, 213: 41-52.
27. Barbieri SS, Eligini S, Brambilla M, Tremoli E, Colli S: Reactive oxygen species mediate cyclooxygenase-2 induction during monocyte to macrophage differentiation: critical role of NADPH oxidase. Cardiovasc Res 2003, 60: 187-197.
28. Dusser D, Bravo ML, Iacono P: The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006, 27: 547-555.
29. Tashkin DP, Celli BR, Senn S, Burkhart D, Kesten S, Menjoge SS, Decramer M: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359: 1543-1554.
30. Powrie DJ, Wilkinson TM, Donaldson GC, Jones PW, Scrine K, Viel K, Kesten S, Wedzicha JA: Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007, 30: 472-478.
31. Perng D-W, Tao CW, Su K-C, Tsai C-C, Liu L-Y, Lee Y-C: Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. Eur Respir J 2009, 38: 778-784.
32. Groenewegen KH, Postma DS, Hop WC, Wielders PLML, Schlösser NJJ, Wouters EFM: Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008, 133: 350-357.
33. Burge PS, Calverley PMA, Jones PW, Anderson JA, Maslen TK: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructiv pulmonary disease: the ISOLDE trial. BMJ 2000, 320: 1297-1303.
34. Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC: Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD cause immediate and sustained disease deterioation: a randomised controlled trial. Thorax 2005, 60: 480-487.
35. Jones PW, Willits LR, Burge PS, Calverley PMA: Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary diasase exacerbations. Eur Respir J 2003, 21: 68-73.
36. Vestbo J, Sørensen T, Lange P, Brix A, Torre P, Viskum K: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999, 355: 1819-1823.
37. Calverley PMA, Anderson JA, Celli BR, Ferguson GT, Jenkins C, Jones PW, Yates J, Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356: 775-789.
38. National Institute for Clinical Excellence: Chronic obstructive pulmonary disase. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004, 59: 1-232.
39. Szafranski W, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003, 21: 74-81.
40. Balbi B: COPD, is chemotaxis the key ? Chest 2003, 123: 983-986.
41. Wessler IK, Kirkpatrick J: The non-neuronal cholinergic system: an emerging drug target in the airways. Pulm Phamacol Therapeutics 2001, 14: 423-434.
42. Groneberg DA, Quarcoo D, Frossard N, Fischer A: Neurogenic mechanisms in bronchial inflammatory diseases. Allergy 2004, 59: 1139-1152.
43. Sato E, Koyama S, Okubo Y, Kubo K, Sekiguchi M: Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity. Am J Physiol (Lung Cell Mol Physiol) 1998, 18: L970-L979.
44. Profita M, Chiappara G, Mirabella F, Di Giorgi R, Chimenti L, Costanzo G, Bellia V, Bousquet J, Vignola AM: Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax 2003, 58: 573-579.
45. Drost E, MacNee W: Potential role of IL-8, platelet-activating factor and TNF-alpha in the sequestration of neutrophils in the lung: effects on neutrophil deformability, adhesion receptor expression, and chemotaxis. Eur J Immunol 2002, 32: 393-403.
46. ATP channel openers activate the ERK kinase by an oxidant-dependent mechanism. Am J Physiol Cell Physiol 2002, 283: C273-C281.
47. ATP channel opening. J Mol Cell Cardiol 2003, 35: 653-660.
48. Barret EG, Johnston C, Oberdorster G, Finkelstein JN: Silica-induced chemokine expression in alveolar type II cells is mediated by TNF alfa induced oxidant stress. Am J Physiol Lung Cell Mol Physiol 1999, 276: L979-L988.
49. De Keulenaer GW, Ushio-Fukai M, Yin Q, Chung AB, Lyons PR, Ishizaka N, Rengarajan K, Taylor WR, Alexander RW, Griendling KK: Convergence of redox-sensitive and mitogen-activated protein kinase signaling pathways in tumor necrosis factor-alpha-mediated monocyte chemoatractant protein-1 induction in vascular smooth muscle cells. Arteriscler Throm Vasc Biol 2000, 20: 385-391.
50. Wollin L, Pieper MP: Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD [abstract]. Am J Respir Crit Care Med 2009, 179: A6196.
51. Profita M, Bonanno A, Siena L, Ferraro M, Montalbano AM, Pompeo F, Riccobono L, Pieper MP, Gjomarkaj M: Acetylcholine mediates the release of IL-8 in human bronchial epithelial cells by a NFkB/ERK-dependent mechanism. Eur J Pharmacol 2008, 582: 145-153.
52. Profita M, Di Giorgi R, Sala A, Bonanno A, Riccobono L, Mirabella F, Gjomarkaj M, Bonsignore G, Bousquet J, Vignola AM: Muscarinic receptors, leukotriene B4 production andneutrophilic inflammation in COPD patients. Allergy 2005, 60: 1361-1369.
53. Metzen J, Bittinger F, Kirkpatrick J, Kilbinger H, Wessler IK: Proliferative effect of acetylcholine on rat trachea epithelial cells is mediated by nicotinic receptors and muscarinic receptors of the M1-subtype. Life Sci 2003, 72: 2075-2080.
54. Koyama S, Sato E, Nomura H, Kubo K, Nagai S, Izumi T: Acetylcholine and substance P stimulate bronchial epithelial cells to release eosinophilic chemotactic activity. J Appl Physiol 1998, 84: 1528-1534.
55. Salari H, Chan-Yeung M: Release of 15-hydroxyeicosatetraenoic acid (15-HETE) and prostaglandin E2 (PGE2) by cultured human bronchial epithelial cells. Am J Respir Cell Mol Biol 1989, 1: 245-250.
56. Blaas SH, Schulz C, Stoelcker B, Wacker M, Ruhland B, Pfeifer M: Carbachol induced proinflammatory cytokine release from primary bronchial epithelial cells [abstract]. Am J Respir Crit Care Med 2007, 175: A178.
57. Sato KZ, Fujii T, Watanabe Y, Yamada S, Ando T, Kazuko F, Kawashima K: Diversity of mRNA expression for muscarinic acetylcholine receptor subtypes and neuronal nicotinic acetylcholine receptor subunits in human mononuclear leukocytes and leukemic cell lines. Neurosci Lett 1999, 266: 17-20.
58. Bany U, Ryzewski J, Maslinski W: Relative amounts of mRNA encoding four subtypes of muscarinic receptors (M2-M5) in human peripheral blood mononuclear cells. J Neuroimmunol 1999, 97: 191-195.
59. Gahring LC, Rogers SW: Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cells. AAPS J 2006, 7: E885-94.
60. Meurs H, Timmermans A, de Monchy JG, Zaagsma J, Kauffman H: Lack of coupling of muscarinic receptors to phosphoinositide metabolism and adenylyl cyclase in human lymphocytes and polymorphonuclear leukocytes: studies in healthy subjects and allergic asthmatic patients. Int Arch Allergy Immunol 1993, 100: 19-27.
61. Gwilt CR, Donnelly LE, Rogers DF: The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation? Pharmacol Ther 2007, 115: 208-222.
62. Matsunaga K, Kleine TW, Friedman B, Yamamoto Y: Involvement of nicotinic acetylcholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to Legionella pneumophila infection by nicotine. J Immunol 2001, 167: 6518-6524.
63. Roffel AF, Elzinga CR, Zaagsma J: Muscarinic M3 receptors mediated contraction of human central and peripheral airway smooth muscle. Pulm Pharmacol 1990, 3: 47-51.
64. Roffel AF, Elzinga CR, Amsterdam van RG, de Zeeuw RA, Zaagsma J: Muscarinic M2 receptor in bovine tracheal smooth muscle: discrepancies between binding and function. Eur J Pharmacol 1988, 153: 73-82.